Short answer
ClearPoint Neuro, Inc. (CLPT) filed an 8-K current report with the SEC on August 3, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure), Item 2.02 (Results of Operations and Financial Condition). Q2 fiscal 2026 financial results for quarter ended June 30, 2026 announced.
ClearPoint Neuro, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 financial results for quarter ended June 30, 2026 announced
- Full revenue, earnings and operating details in Exhibit 99.1 press release
- Results provide updated view of ClearPoint Neuro’s financial performance and outlook
Item 7.01 · Regulation FD Disclosure
- Updated investor presentation furnished as Exhibit 99.2, signaling refreshed messaging for investors and analysts
- Presentation available on ClearPoint Neuro’s investor-relations website for review
- Key operating updates, financial outlook, or strategic claims require examination of Exhibit 99.2
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $10.9M, up 18% YoY, driven by neurosurgery navigation and therapy revenue growth of 62% to $5.6M
- Biologics and drug delivery revenue fell 15% to $4.0M, reflecting lower biopharma trial-related product shipments
- Gross margin improved to 62% from 60%, but operating expenses rose 51% to $17.0M, widening net loss to $11.3M
- 2026 revenue guidance reset to $48.0M-$52.0M as investment shifts toward clinical support, CAL, focused ultrasound, robotics, and software
- Cash declined to $29.4M from $45.9M, with $15.0M used in operating activities and long-term notes payable of $50.2M
Item EX-99.2 · Exhibit EX-99.2
- Investor presentation outlines a five-pillar strategy targeting $500m revenue, adding commercial drug delivery to four existing businesses
- 2026 revenue guidance $48.0m-$52.0m, versus $37.0m in 2025
- Cash and equivalents $29.4m, gross margin 63%, and 160+ employees as of June 30, 2026
- Platform scale: 175+ active global centers, 60+ pharma partners, 25+ clinical trials, and 10+ programs under FDA expedited review
- Management targets $200m annual revenue from a $1.0B existing market plus $300m annually from 20,000 cell and gene therapy procedures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ClearPoint Neuro, Inc. 8-K filings
Get the next CLPT 8-K as it lands
Follow CLPT for push alerts, or ask the research agent what this filing means.